Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,558 questions in 115 reviews · Vascular
current versionsNo studies 346 · 22.2%Ungraded 90 · 5.8%Very low 281 · 18%Low 477 · 30.6%Moderate 313 · 20.1%High 51 · 3.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
VTE extended prophylaxis vs another VTE extended prophylaxis Major bleedingd · patients with unprovoked venous thromboembolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in… (2017) · Cochrane | OR 3.06 [0.37, 25.51] | 1 study · 1389 participants | Moderate |
VTE extended prophylaxis vs another VTE extended prophylaxis All‐cause mortalitye · patients with unprovoked venous thromboembolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in… (2017) · Cochrane | no estimate extracted | NR | No studies |
VTE extended prophylaxis vs another VTE extended prophylaxis Clinically relevant non‐major bleedingf · patients with unprovoked venous thromboembolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in… (2017) · Cochrane | OR 0.84 [0.37, 1.94] | 1 study · 1389 participants | Moderate |
VTE extended prophylaxis vs another VTE extended prophylaxis Strokeg · patients with unprovoked venous thromboembolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in… (2017) · Cochrane | no estimate extracted | NR | No studies |
VTE extended prophylaxis vs another VTE extended prophylaxis Myocardial infarction · patients with unprovoked venous thromboembolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in… (2017) · Cochrane | no estimate extracted | NR | No studies |
Extended prophylaxis vs placebo Recurrent VTEc · patients with unprovoked venous thromboembolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in… (2017) · Cochrane | OR 0.63 [0.38, 1.03] | 5 studies · 2043 participants | Moderate |
Extended prophylaxis vs placebo Major bleedinge · patients with unprovoked venous thromboembolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in… (2017) · Cochrane | OR 1.84 [0.87, 3.85] | 5 studies · 2043 participants | Low |
Extended prophylaxis vs placebo All‐cause mortalityg · patients with unprovoked venous thromboembolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in… (2017) · Cochrane | OR 1 [0.63, 1.57] | 5 studies · 2043 participants | Moderate |
Extended prophylaxis vs placebo Clinically relevant non‐major bleedingh · patients with unprovoked venous thromboembolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in… (2017) · Cochrane | OR 1.78 [0.59, 5.33] | 4 studies · 1672 participants | Low |
Extended prophylaxis vs placebo Strokei · patients with unprovoked venous thromboembolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in… (2017) · Cochrane | OR 1.15 [0.39, 3.46] | 2 studies · 1224 participants | Low |
Extended prophylaxis vs placebo Myocardial infarction · patients with unprovoked venous thromboembolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in… (2017) · Cochrane | OR 1 [0.35, 2.87] | 3 studies · 1495 participants | Low |
VTE extended prophylaxis vs another VTE extended prophylaxis VTE‐related mortalitya · patients with unprovoked venous thromboembolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in… (2017) · Cochrane | no estimate extracted | NR | No studies |
VTE extended prophylaxis vs another VTE extended prophylaxis Recurrent VTEb · patients with unprovoked venous thromboembolism Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in… (2017) · Cochrane | OR 0.28 [0.15, 0.54] | 1 study · 1389 participants | Moderate |
Growth factors vs placebo or no therapy Major limb amputation ( · people who have been diagnosed with peripheral arterial disease Growth factors for angiogenesis in peripheral arterial disease (2017) · Cochrane | OR 0.99 [0.71, 1.38] | 10 studies · 1075 participants | Moderate |
Growth factors vs placebo or no therapy Any limb amputation ( · people who have been diagnosed with peripheral arterial disease Growth factors for angiogenesis in peripheral arterial disease (2017) · Cochrane | OR 0.56 [0.31, 0.99] | 6 studies · 415 participants | Low |
Growth factors vs placebo or no therapy Death ( · people who have been diagnosed with peripheral arterial disease Growth factors for angiogenesis in peripheral arterial disease (2017) · Cochrane | OR 0.99 [0.69, 1.41] | 12 studies · 1371 participants | Moderate |
Growth factors vs placebo or no therapy Serious adverse events ( · people who have been diagnosed with peripheral arterial disease Growth factors for angiogenesis in peripheral arterial disease (2017) · Cochrane | OR 1.09 [0.79, 1.5] | 13 studies · 1411 participants | Moderate |
Growth factors vs placebo or no therapy Any adverse event ( · people who have been diagnosed with peripheral arterial disease Growth factors for angiogenesis in peripheral arterial disease (2017) · Cochrane | OR 1.1 [0.73, 1.64] | 13 studies · 1411 participants | Moderate |
NMES vs alternative prophylaxis Total DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | OR 1.01 [0.6, 1.7] | 6 studies · 415 participants | Low |
NMES vs no prophylaxis PE · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | OR 0.36 [0.12, 1.07] | 1 study · 77 participants | Low |
NMES vs no prophylaxis Total VTE · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | OR 0.23 [0.09, 0.59] | 1 study · 77 participants | Low |
NMES vs no prophylaxis Bleeding (major and minor) · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 4 studies · 576 participants | Ungraded |
NMES vs low‐dose heparin Total DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | OR 2.78 [1.19, 6.48] | 2 studies · 194 participants | Low |
NMES vs low‐dose heparin Asymptomatic DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | OR 1.61 [0.4, 6.43] | 1 study · 89 participants | Low |
NMES vs low‐dose heparin Symptomatic DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | OR 0.4 [0.02, 10.07] | 1 study · 89 participants | Low |
NMES vs low‐dose heparin PE · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 2 studies · 194 participants | Ungraded |
NMES vs low‐dose heparin Total VTE · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 2 studies · 194 participants | Ungraded |
NMES vs low‐dose heparin Bleeding (major and minor) · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 2 studies · 194 participants | Ungraded |
NMES vs Dextran 40 Total DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | OR 0.63 [0.18, 2.19] | 1 study · 72 participants | Low |
NMES vs alternative prophylaxis Asymptomatic DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | OR 1.61 [0.4, 6.43] | 1 study · 89 participants | Low |
NMES vs Dextran 40 Asymptomatic DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 72 participants | Ungraded |
NMES vs Dextran 40 Symptomatic DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 72 participants | Ungraded |
NMES vs Dextran 40 PE · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | OR 1.5 [0.39, 5.84] | 1 study · 72 participants | Low |
NMES vs Dextran 40 Total VTE · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | OR 0.92 [0.34, 2.52] | 1 study · 72 participants | Low |
NMES vs Dextran 40 Bleeding (major and minor) · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 72 participants | Ungraded |
Combined NMES and low‐dose heparin vs no prophylaxis Total DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | OR 0.08 [0.01, 0.76] | 1 study · 32 participants | Low |
Combined NMES and low‐dose heparin vs no prophylaxis Asymptomatic DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 32 participants | Ungraded |
Combined NMES and low‐dose heparin vs no prophylaxis Symptomatic DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 32 participants | Ungraded |
Combined NMES and low‐dose heparin vs no prophylaxis PE · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 32 participants | Ungraded |
Combined NMES and low‐dose heparin vs no prophylaxis Total VTE · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 32 participants | Ungraded |
NMES vs alternative prophylaxis Symptomatic DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | OR 0.4 [0.02, 10.07] | 1 study · 89 participants | Low |
Combined NMES and low‐dose heparin vs no prophylaxis Bleeding (major and minor) · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 32 participants | Ungraded |
Combined NMES and low‐dose heparin vs low‐dose heparin Total DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | OR 0.07 [0.01, 0.68] | 1 study · 31 participants | Low |
Combined NMES and low‐dose heparin vs low‐dose heparin Asymptomatic DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 31 participants | Ungraded |
Combined NMES and low‐dose heparin vs low‐dose heparin Symptomatic DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 31 participants | Ungraded |
Combined NMES and low‐dose heparin vs low‐dose heparin PE · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 31 participants | Ungraded |
Combined NMES and low‐dose heparin vs low‐dose heparin Total VTE · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 31 participants | Ungraded |
Combined NMES and low‐dose heparin vs low‐dose heparin Bleeding (major and minor) · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 31 participants | Ungraded |
NMES vs GCS Total DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | OR 0.32 [0.01, 8.27] | 1 study · 36 participants | Low |
NMES vs GCS Asymptomatic DVT · participants at risk of venous thromboembolism Neuromuscular electrical stimulation for the prevention of venous thromboembolism (2017) · Cochrane | no estimate extracted | 1 study · 36 participants | Ungraded |